ID :
189466
Sat, 06/18/2011 - 15:02
Auther :
Shortlink :
http://m.oananews.org//node/189466
The shortlink copeid
Thai researcher: “Cyclin D1” protein reduction will boost cancer treatments
BANGKOK, June 18 (TNA) - Leading Thai and US scientists have jointly found that a lower presence of “Cyclin D1” protein can enhance cancer treatments.
Dr. Siwanon Jirawatnotai, an expert from Thailand’s Institute of Molecular Biosciences at Mahidol University, who heads the joint research with the U.S.-based Dana-Farber Cancer Institute as well as Universities of Harvard and Stanford, announced the discovery on Friday, saying that the suppression of “Cyclin D1” could lead to more effective cancer treatments.
Cyclin D1, present in most cancerous cells, was known help control human bodies against any genetic mutation, but any abnormal variation of the protein could have a reverse effect, leading to cancer development.
Dr. Siwanon said tests conducted by his research team have shown that Cyclin D1 is responsible for failing chemo- and radiation therapies, as it repairs broken DNA molecules in cancerous cells after each treatment.
The joint study indicated that the rate of genetic mutation of the Cyclin D1 was found in most cancer types, including breast, colorectal, lymphoma, skin cancer and prostate cancer. (TNA)
Dr. Siwanon Jirawatnotai, an expert from Thailand’s Institute of Molecular Biosciences at Mahidol University, who heads the joint research with the U.S.-based Dana-Farber Cancer Institute as well as Universities of Harvard and Stanford, announced the discovery on Friday, saying that the suppression of “Cyclin D1” could lead to more effective cancer treatments.
Cyclin D1, present in most cancerous cells, was known help control human bodies against any genetic mutation, but any abnormal variation of the protein could have a reverse effect, leading to cancer development.
Dr. Siwanon said tests conducted by his research team have shown that Cyclin D1 is responsible for failing chemo- and radiation therapies, as it repairs broken DNA molecules in cancerous cells after each treatment.
The joint study indicated that the rate of genetic mutation of the Cyclin D1 was found in most cancer types, including breast, colorectal, lymphoma, skin cancer and prostate cancer. (TNA)
